Ortho Pharmaceutical Corp. v. Sona Distributors, Inc.

117 F.R.D. 170, 1986 U.S. Dist. LEXIS 16502
CourtDistrict Court, S.D. Florida
DecidedDecember 12, 1986
DocketNo. 86-0032-CIV
StatusPublished
Cited by3 cases

This text of 117 F.R.D. 170 (Ortho Pharmaceutical Corp. v. Sona Distributors, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ortho Pharmaceutical Corp. v. Sona Distributors, Inc., 117 F.R.D. 170, 1986 U.S. Dist. LEXIS 16502 (S.D. Fla. 1986).

Opinion

AMENDED MEMORANDUM OPINION AND ORDER GRANTING, IN PART, PLAINTIFFS’ MOTION FOR RECOVERY OF COSTS

SPELLMAN, District Judge.

This Court is presented with a basic fraud claim. Ortho Pharmaceutical Corporation (Ortho), manufactures drugs for sale in both the United States and abroad. Johnson & Johnson (Hong Kong), is a subsidiary of its larger parent, and has an exclusive contract to sell Ortho drugs in Hong Kong, extending also into parts of Mainland China. Sona Distributors, Inc. (Sona), has a Florida office in which it sells pharmaceuticals to hospitals and drug stores. Elmcrest Trading, LTD (Elmcrest) is a trading company based in Hong Kong. Sona and Elmcrest have both commonly owned and managed in that the shareholders and directors of each company are virtually identical to that of the other.

The underlying dispute revolves around a contract that Johnson & Johnson entered into with a Mr. Yin of Chung Ching Dispensary in Hong Kong. The contract was for the sale of Ortho manufactured drugs among others sold by Johnson & Johnson, but the sale was conditioned upon the restriction that Chung Ching would market the drugs in Mainland China only, and that under no circumstances were the drugs to be resold in the United States. The reason for this restriction was based on Johnson & Johnson’s market strategies abroad, which in this case, allowed for the sale of these drugs in the far east at prices well below that which it could command even at the wholesale level in the United States. The Plaintiffs allege that the Defendants conspired with Mr. Yin, and through Elmcrest purchases from Mr. Yin, Sona was ultimately able to acquire Ortho drugs at “bargain” prices for distribution and resale in the United States. Defendants do not challenge that Mr. Yin falsely misrepresented the ultimate destination for the drugs, in fact, under deposition, Mr. Yin himself admitted that he never intended the drugs for resale in Mainland China. Defendants challenge, however, that they had anything to do with Mr. Yin, and that they neither told him to misrepresent the drugs’ ultimate destination, nor were they aware of any restrictions on resale. In support of this contention, Defendants urge that there was nothing in writing evidencing a resale restriction. Furthermore, the drugs themselves were without labeling instructions forbidding their entry into the United States pharmaceutical market. On the contrary, Defendants argue that the labels were not even printed in Chinese, suggesting that no reasonable person would have cause to believe that the drugs could not be resold to other markets.

The focus of this opinion, however, is on Plaintiffs’ motion to assess costs against the Defendants under Rules 11 and 37(b) of the Federal Rules of Civil Procedure. The Rule 11 claim is based on what the Plaintiffs describe as a “frivolous” motion to dismiss for lack of personal jurisdiction, which the Defendant ultimately abandoned. The other claim for cost recovery is based on what the Plaintiffs characterize as dilatory discovery tactics. Aftay reviewing these concurrent motions, it is hereby

ORDERED AND ADJUDGED that the Rule 11 motion is GRANTED, but the Court will DENY the motion on Rule 37 discovery abuses. The Plaintiffs, within 30 days from the signing of this order, will provide this Court with an accurate itemized statement showing the costs and fees incident to their defense of Elmcrest’s motion to dismiss.

OPINION

A. Rule 11 Sanctions

Elmcrests’ unsuccessful attempt to avoid participating in this litigation on the theory that this Court’s jurisdictional powers could not extend to this particular Hong Kong corporation was not only an incompetent motion at its inception, but it also appears as though its submission was so lacking in good faith that Rule 11 sanctions at this time are appropriate and necessary to both compensate the Plaintiffs [172]*172for the costs incurred in defending against this “frivolous” claim, and in preventing the Defendants from committing future abuses in this litigation and in others possibly to come. There is no question that the Defendants are not only owned and managed by the same individuals, but that their operations are so closely intertwined in their business practices and financial well being, particularly as it relates to this litigation, that there is no mistaking that personal jurisdiction attaches to the Hong Kong affiliate, Elmcrest. Defendants’ attempts to convince this court that Elmcrest is not in fact the alter ego of Sona have been unavailing.

The recovery of Rule 11 costs in this instance is not nearly as relevant a question as is the proper timing for the imposition of these sanctions. This Court already finds that the motion to dismiss on personal jurisdiction grounds was meritless, and that the Plaintiffs are entitled to recover costs attendant to the defense of this motion. This Court finds, however, that the imposition of Rule 11 sanctions under these circumstances should be made now and not at the conclusion of trial.

When an attorney signs a pleading or motion, he or she in essence certifies that he has drafted the document in good faith and that the allegations are true and not intended to delay the litigation or harass the opposition.1 The test in judging whether the conduct gives rise to Rule 11 sanctions is an objective one. Congress amended the rule in 1983, and in doing so, eliminated the subjective good faith standard that had existed earlier, and which required a finding that the attorney’s conduct was either willful or intentional. The advisory committee notes make it clear that “the [new] standard is less stringent than the original jgood faith formula and thus it is expected that a greater range of circumstances will trigger its violation.” Fed.R.Civ.P. 11 advisory committee note.2

A recent decision in the Court of. Appeals for the Ninth Circuit has clarified a confusing issue in the application of Rule 11. The opinion, In re Yagman, 796 F.2d 1165 (9th Cir.1986), focused on the'proper timing that a court should follow when considering the imposition of Rule 11 sanctions. In that case, the court reversed and remanded a ruling that imposed an excessive award of sanctions because the lower court waited [173]*173until the conclusion of trial to discipline the attorney’s conduct. The abuse that the court ultimately sanctioned continued throughout trial unabated. The ninth circuit urged that when

sanctions are warranted by those circumstances, the court should not waiver in imposing them____
... [To not do so] flies in the face of the primary purpose of sanctions, which is to deter subsequent abuses. This policy is not well served by tolerating abuses during the course of an action and then punishing the offender after trial is at an end. A proper sanction assessed at the time of the transgression will ordinarily have some measure of deterrent effect on subsequent abuses and resultant sanctions. Such ‘prompt action helps enhance the credibility of the rule and, by deterring further abuse, achieve its therapeutic purpose.’

In re Yagman,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brooks v. Giesey
432 S.E.2d 339 (Supreme Court of North Carolina, 1993)
Mercedes Lighting and Electrical Supply, Inc. v. DEPT. GEN. SERV.
560 So. 2d 272 (District Court of Appeal of Florida, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
117 F.R.D. 170, 1986 U.S. Dist. LEXIS 16502, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ortho-pharmaceutical-corp-v-sona-distributors-inc-flsd-1986.